INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $313 | -17.6% | 6,000 | 0.0% | 0.02% | -25.0% |
| Q2 2023 | $380 | +9.5% | 6,000 | -6.2% | 0.03% | -3.0% |
| Q1 2023 | $347 | +2.4% | 6,400 | 0.0% | 0.03% | -15.4% |
| Q4 2022 | $339 | -99.9% | 6,400 | 0.0% | 0.04% | +5.4% |
| Q3 2022 | $298,000 | -18.4% | 6,400 | 0.0% | 0.04% | -15.9% |
| Q2 2022 | $365,000 | -9.7% | 6,400 | -3.0% | 0.04% | +2.3% |
| Q1 2022 | $404,000 | +8.6% | 6,600 | -7.0% | 0.04% | +4.9% |
| Q4 2021 | $372,000 | +40.4% | 7,100 | 0.0% | 0.04% | +5.1% |
| Q3 2021 | $265,000 | -27.8% | 7,100 | -21.1% | 0.04% | -29.1% |
| Q2 2021 | $367,000 | +10.2% | 9,000 | -8.2% | 0.06% | +3.8% |
| Q1 2021 | $333,000 | -4.9% | 9,800 | -10.9% | 0.05% | 0.0% |
| Q4 2020 | $350,000 | +26.4% | 11,000 | +1.9% | 0.05% | +26.2% |
| Q3 2020 | $277,000 | +1.8% | 10,800 | +1.9% | 0.04% | +2.4% |
| Q2 2020 | $272,000 | – | 10,600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |